|
Product name |
|
Presentation |
Country of Origin |
Composition |
Indication |
Dosage |
Typhim Vi |
Typhoid vaccine |
Prefilled syringe (0.5ml) |
France |
Each vaccinating dose contains solution of
purified Vi capsular polysaccharide of Samonella typhi
25mcg, |
Prevention of typhoid fever in adults and
children |
A single injection SC or IM provides
protection for a minimum of 3years.
Typhoid fever prevention becomes effective 2-3 weeks after
injection. |
|
Avaxim 80U |
Inactivated hepatitis A vaccine, adsorbed |
Prefilled syringe
(0.5ml) |
France |
Each 0.5ml dose contains hepatitis A virus (GBM
strain), inactivated, 80U |
Acute immunization against hepatitis A virus
in children 12months to 15 years inclusive, who are at risk
either of contaminating or spreading infection or of
life-threatening disease if infected. |
Primary vaccination is achieved 1 single
dose of vaccine. Recommended dosage: 0.5ml for each
injection.
In order to provide long term protection, a booster dose is
recommended 6-18months after the initial dose.
The vaccine must be injected by IM route at the deltoid
region. |
|
Avaxim 160U |
Inactivated hepatitis A vaccine, adsorbed |
Prefilled syringe
(0.5ml) |
France |
Each 0.5ml dose contains hepatitis A virus (GBM
strain), inactivated, 160U |
Acute immunization against hepatitis A virus
in adolescents from 16 years and in adults. |
0.5ml for each injection. Primary
vaccination consists of one dose of vaccine followed by
booster injection 6-12 months later.
The vaccine must be injected by IM route at the deltoid
region. |
|
Euvax B :
Adult dose
Euvax B :
Paed dose |
Recombinant Hepatitis B vaccine |
Vial
0.5ml , 1ml |
Korea |
Adult dose: One ml of Euvax B contains
purified HBsAg 20mcg.
Paed dose: 0.5 ml of Euvax B contains purified HBsAg 10mcg. |
Immunization against infection caused by all
known subtypes of hepatitis B virus. |
Dosage:
Adults (from 16 years): 1ml containing 20mcg of HBsAg
Children (Neonates, Infants and children ≤15 years): 0.5ml
containing 10mcg of HBsAg
Administration: IM use only.
The immunization regimen consists of 3 doses of vaccines :
1st dose- At Elected date
2nd dose- One month after the 1st dose
3rd dose- Six months after the 1st dose |
|
Verorab |
Inactivated purified Rabies vaccine prepared
on Vero cells |
Vial 1 dose + syringe (diluent)
(0.5ml) |
France |
Each vial of freezed-dried product contain
Rabies virus (Wister Rabies PM/WI 38 1503-3M strain) ≥ 2.5
iu |
Pre-exposure prevention of rabies & Rabies
prevention after confirmed of suspected exposure. |
Thae vaccine is administered by the IM
route only, in the deltoid area for adults or the anterolateral area of the thigh muscles of the children. Do
not inject in the gluteal area.
Prevention or Pre-exposure vaccination
- see Table 1
Curative or Post exposure vaccination: see
Table 2
|
|
Favirab |
Equine Rabies Immune Globulin (ERIG) |
5ml Vial |
France |
Each ml vial contains F(ab')2 fragments of
equine rabies immune globulin(not less than 200iu). |
Seroprophylaxis (ie. Prevention by injecting
antibodies of rabies) in subjects suspected to be exposed to
the rabies virus. Favirab is to be administered
exclusively in association with rabies vaccination, acording
to the recommendation of the WHO expert committee on rabies
(1992;824;61) |
Adults & Children: Recommended dose: 40iu/kg
body weight
Favirab must be injected slowly by the IM route. If
anatomically feasible, as much as possible, the dose should
be infiltrated around and into the wounds. The remainder of
the dose should be administered IM (into the gluteal region)
in a single injection. |
|
Tetavax |
Adsorbed Tetanus Vaccine |
Amp 1 dose (0.5ml) x 20's |
France |
Each immunizing dose contain purified
tetanus toxoid 1 immunizing dose (not less than 40 iu) |
Prevention of tetanus |
For isolated primary immunization in an
adult, because of the high antigenicity of vaccine, 2
injections 4-6 weeks apart followed by a booster 6-12 months
after the second injection are adequate.
Booster: 1 injection every 10 years. |
|
Tetanea |
Equine tetanus immunoglobulin |
Amp 1500iu/ml x 20's |
France |
Equine tetanus immunoglobulin F(ab)'2
fragments 1500iu/ml |
Prevention of tetanus in persons with recent
injuries that might be contaminated with tetanus bacillus
spores and who have not received vaccination in the previous
10 years or whose prior vaccination schedule is incomplete
or unknown. |
Tetaea 1500iu/ml is to be administered as
soon as possible after the injury. Children and adults
receive the same dose. This dose may be doubled: In the
event of anfractuous or infected wounds; if the injection is
delayed (24hrs after the injury); in the adults of above
average weight; in subjects suffering from burns, necrotic
lesions, state of shock with haemorrhaging.
Injected by IM route into the deltoid or the upper outer
quadrant of the gluteal region. |
|
Act-Hib |
Haemophilus influenzae type b conjugate
vaccine |
1 Vial
+ 1 Syringe diluent(0.5ml) |
France |
Act-Hib contains 1 immunizing dose of
freeze-dried vaccine containing an equivalent to 10mcg of
capsular polysaccharide of Haemophilus influenzae type b
conjugate to tetanus protein. |
For the prevention of invasive disease in
infants from 2 months caused by Haemophilus influenzae type
b eg. meningitis, septicaemia, pneumonia, etc. |
Injected by IM or SC route after
reconstitution.
Children from 2 years- in the deltoid region,
infants up to 12 years- in the anterolateral surface of
the thigh (middle third).
1-5 years: 1 single injection
6-12mths: 2 injections at 1 to 2 mth interval
followed by a booster 12 mth after the 2nd dose
2-6mths: 3 injections at 1 to 2 mth interval followed
by a booster 12 mth after the 3rd dose |
|
Tetract-Hib |
Haemophilus influenzae type b conjugate
vaccine, adsorbed diphtheria, tetanus and pertussisspace
vaccine |
1 Vial
powder
+ 1 Syringe (0.5ml) |
France |
Tetract-Hib contains 1vial of Act-Hib
containing Haemophilus influenzae type b conjugate to
tetanus protein 10mcg, plus 1 syringe of DTP (suspension for
injection for 1 immunizing dose) containing purified
diphtheria toxoid 30 iu, purified tetanus toxoid 60 iu,
Bordetella pertussis minimum of 4 iu. |
Combined prevention of invasive diseases
caused by Haemophilus influenzae type b and of diphtheria,
tetanus and pertussis. |
The injection is recommended in the
anterolateral surface of the thigh (middle third) by IM or
SC route but IM route should be preferred.
The vaccine can be administered to infants from the age of 2
months with 3 injections of 1 dose of vaccine (0.5ml) at
intervals of 1 or 2 months. Booster: 1 injection a year
after primary vaccination.
|
|
Tetraxim |
Diphtheria, tetanus, acellular pertussis and
inactivated poliomyelitis vaccine |
Prefilled syringe (0.5ml) |
France |
Each 0.5ml contains:-
Diphtheria toxoid ≥30iu, tetanus toxoid ≥40iu,
Bordetells
pertussis antigens: Toxoid 25mcg, filamentous heamagglutinin
25mcg, inactivated type 1 poliomyelitis virus 40DU,
inactivated type 2 poliomyelitis virus 8DU, inactivated type
3 poliomyelitis virus 32DU
(DU= D antigen unit) |
Protection against diphtheria, tetanus,
pertussis and poliomyelitis from the age of 2 months |
The usual recommended schedule includes
primary vaccination consisting of 3 injections at an
interval of 1-2 months from the age of 2months followed by 1
booster injection 1 year after primary vaccination within
the second year of life and another one between 5 to 13
years according to national official recommendations. |
|
Pentaxim |
Adsorbed diphtheria, tetanus, acellular
pertussis, inactivated poliomyelitis vaccine and Haemophilus
influenzae type b conjugate vaccine |
1 Vial
+ 1 Syringe (0.5ml) |
France |
Each 0.5ml contains:- Diphtheria toxoid
≥30iu, tetanus toxoid ≥40iu, Bordetells pertussis antigens (Toxoid
25mcg, filamentous heamagglutinin 25mcg), inactivated type 1
poliomyelitis virus 40DU, inactivated type 2 poliomyelitis
virus 8DU, inactivated type 3 poliomyelitis virus 32DU (DU=
D antigen unit), Haemophilus influenzae type b
conjugate to tetanus protein 10mcg |
Combined prevention of invasive diseases
caused by Haemophilus influenzae type b and of diphtheria,
tetanus, pertussis and poliomyelitis. |
The usual recommended schedule includes
primary vaccination consisting of 3 injections at an
interval of 1-2 months from the age of 2months.
Booster vccination 1 injection 1 year after primary
vaccination , generally between 16 and 18 months. |
|
Trimovax |
Attenuated live measles virus, rubella virus
and attenuated live mumps virus |
1 Vial
+ 1 Syringe diluent (0.5ml) |
France |
Each vial of freeze-dried product contains
at least 1000 CCID 50 of hyperattenuated live measles virus
(Schwarz strain), at least 5000 CCID 50 of attenuated live
mumps virus (Urabe strain), and at least 1000 CCID 50 of
attenuated rubella virus (Wistar RA 27/3M strain). |
Combined prevention of measles, mumps and
rubella from 12 months of age in children of both sexes. For
children living in communities, this limit may be reduced to
9 months. |
The combined triple vaccination is given by
single injection recommended from 12 months of age. However
a second vaccination is recommended 6 months later in
children in children vaccinated before 12 months of age. A
2nd injection may be given from 4 years of age. |
|
Okavax |
Live attenuated varicella virus vaccine Biken
TM |
1 Vial
power
+ 1 Vial diluent |
Japan |
Each vial contains attenuated live varicella
zoster virus (oka strain) not less than 1,000 PFU. |
Prevention of varicella |
One dose of 0.5ml is injected SC to individuals >12months with no history of varicella. |
|
Meningo A+C |
Meningococcal polysaccharide vaccine A+C |
1 Vial
+ 1 Syringe diluent (0.5ml) |
France |
Each dose of vaccine contains a
lyophillisate of purified polysaccharide of Neisseria
meningitidis group A (50mcg) and group C (50mcg) |
Prevention of cerebrospinal meningitis
caused by Meningococci group A and C |
Vaccination compromises a single injection
administered from the age of 24months onwards by SC or IM
route.
The duration of postvaccinal immunity is currently 3 years. |
|
Pneumo 23 |
Polysaccharide pneumococcal vaccine |
Prefilled syringe (0.5ml) |
France |
Pneumo 23 contains polysaccharides of
Streptococcus pneumoniae, serotypes 1,2,3,4,5,6B,
7F,8,9N,9V,10A,11A,
12F,14,15B,17F,18C,
19A,19F,20,22F,23F,33F
(25mcg for each of 23 serotypes for one 0.5ml dose) |
Prevention of pneumococcal infections, in
particular, pneumonia caused by the serotypes contained in
the vaccines for subjects at risk from the age of 2 years. |
Primary vaccination, Revaccination: one
0.5ml injection.
The preferred route of administration is IM or SC. |
|
Vaxigrip |
Inactivated influenza veccine (split virion) |
Prefilled syringe 0.25ml,
(0.5ml) |
France |
Each 0.25ml and 0.5ml contains influenza
virus (propagated in eggs) and 7.5 and 15mcg haemagglutinin,
respectively. |
Prevention of influenza, particularly in
subjects showing a high-risk associated complications. |
Adults and children ≥36months: 0.5ml
Children 6-35 months: 0.25ml
Administered by IMor deep sc route. |
